(Q34571752)

3 August 2017

1 reference

title

Oncolytic biotherapy: a novel therapeutic plafform (English)

1 reference

3 August 2017

Lynda K Hawkins

1

1 reference

3 August 2017

Nick R Lemoine

series ordinal

2

1 reference

3 August 2017

David Kirn

series ordinal

3

1 reference

3 August 2017

1 January 2002

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

3

1 reference

3 August 2017

1

1 reference

3 August 2017

17-26

1 reference

Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Reovirus as a novel oncolytic agent

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Reovirus therapy of tumors with activated Ras pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

1 reference

7 January 2021

The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

p53 mutations in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Conditionally replicating herpes vectors for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

A tale of two trials: selectively replicating herpesviruses for brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Viral recombinant vaccines to the E6 and E7 antigens of HPV-16

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Poxvirus vectors: orphaned and underappreciated

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Intergeneric poliovirus recombinants for the treatment of malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Use of preferentially replicating bacteria for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Adenovirus 2 Ip+ locus codes for a 19 kd tumor antigen that plays an essential role in cell transformation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Replication-selective adenoviruses as oncolytic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Immunomodulation of cancer: potential use of selectively replicating agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900618-0

7 January 2021

10.1016/S1470-2045(01)00618-0

Identifiers

DOI

1 reference

release_7zf3fckdk5gnhc3n4jsn2tqavm

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7zf3fckdk5gnhc3n4jsn2tqavm

24 November 2022

mapped directly with Wikidata item

1 reference